Format

Send to

Choose Destination
JAMA Ophthalmol. 2018 Jul 1;136(7):747-752. doi: 10.1001/jamaophthalmol.2018.1501.

Treatment of Nonmetastatic Unilateral Retinoblastoma in Children.

Author information

1
Pediatric Oncology Service, Hospital San Juan de Dios, Santiago, Chile.
2
Hematology-Oncology Service, Hospital J. P. Garrahan, Buenos Aires, Argentina.
3
Oncology Service, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
4
Hematology-Oncology Service, Hospital Sant Joan de Déu, Barcelona, Spain.
5
Hematology-Oncology Service, Hospital Calvo Mackenna, Santiago, Chile.
6
Hematology-Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay.
7
Ophthalmology Service, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
8
Ophthalmology Service, Hospital Calvo Mackenna, Santiago, Chile.
9
Pathology Service, Hospital Calvo Mackenna, Santiago, Chile.
10
Ophthalmology Service, Hospital Sant Joan de Déu, Barcelona, Spain.
11
Pathology Service, Hospital Sant Joan de Déu, Barcelona, Spain.
12
Ophthalmology Service, Hospital San Juan de Dios, Santiago, Chile.
13
Ophthalmology Service, Hospital J. P. Garrahan, Buenos Aires, Argentina.
14
Ophthalmic Pathology Department, Fundación Oftalmologica Malbran, Buenos Aires, Argentina.
15
Pathology Service, Hospital J. P. Garrahan, Buenos Aires, Argentina.
16
Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Washington, DC.
17
Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit.

Abstract

Importance:

Multi-institutional collaborative studies that include large patient populations for the management of retinoblastoma with histopathological risk factors could provide important information for patient management.

Objective:

To evaluate the implementation of a strategy for the management of nonmetastatic unilateral retinoblastoma in children based on standardized diagnostic and treatment criteria.

Design, Setting, and Participants:

This single-arm prospective study applied a strategy based on a single-center experience. The setting was a multicenter study in Latin America (Grupo de America Latina de Oncologia Pediatrica [GALOP]). Participants were children with nonmetastatic unilateral retinoblastoma (staged with the International Retinoblastoma Staging System). The study opened on July 1, 2008, and closed on December 31, 2014. Follow-up was updated until June 30, 2017.

Interventions:

Stage 0 patients (without enucleation) were given conservative therapy without a protocol. Stage I patients (with enucleation and no residual tumor) were divided into a high-risk group (retrolaminar invasion and/or scleral invasion) and a low-risk group (all remaining patients). High-risk children received adjuvant chemotherapy with 4 alternating cycles of regimen 1 (cyclophosphamide [65 mg/kg/d] [plus sodium-2-mercaptoethane sulfonate], idarubicin hydrochloride [10 mg/m2/d], and vincristine sulfate [0.05 mg/kg/d]) and 4 cycles of regimen 2 (carboplatin [500 mg/m2/d, days 1 and 2] and etoposide [100 mg/m2/d, days 1-3]). Low-risk children did not receive adjuvant therapy. Children with buphthalmia received neoadjuvant and adjuvant chemotherapy for a total of 8 cycles.

Main Outcomes and Measures:

Probability of event-free survival (extraocular relapse and death from any cause were considered events).

Results:

Among 187 children registered in the study, 175 were evaluable (92 [52.5%] female; median age, 22 months; age range, 3-100 months). Forty-two were stage 0 children, 84 were stage I low-risk children, and 42 were stage I high-risk children; there were 7 children in the buphthalmia group. With a median follow-up of 46 months, the 3-year probability of event-free survival was 0.97 (95% CI, 0.94-0.99), and the probability of overall survival was 0.98 (95% CI, 0.94-1.00). Stage 0 patients had no events, stage I low-risk patients had 1 event (orbital relapse treated with second-line therapy), stage I high-risk patients had 2 events (1 central nervous system relapse and 1 death from sepsis), and the buphthalmia group had 1 event (orbital relapse, followed by central nervous relapse and death).

Conclusions and Relevance:

Adjuvant therapy may be effective for high-risk unilateral retinoblastoma but is toxic, and neoadjuvant chemotherapy for buphthalmus appears feasible.

PMID:
29799944
PMCID:
PMC6136048
[Available on 2019-05-17]
DOI:
10.1001/jamaophthalmol.2018.1501

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center